Better outcome of high-dose ceftazidime in hemato – oncological patients with infections caused by extensively drug-resistant pseudomonas aeruginosa
Conclusion: Ceftazidime in high doses is a very potent ATB for the treatment of XDRP. aeruginosa infections in neutropenic cancer with acceptable toxicity.
Source: Mediterranean Journal of Hematology and Infectious Diseases - Category: Hematology Authors: Alzbeta Zavrelova, Jakub Radocha, Pavla Paterova, Pavel Zak, Benjamin Visek, Martin Sima Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Hematology | Infectious Diseases | Neurology | Statistics | Study | Toxicology